ISPOR Europe 2025: first look at the conference program
Marking its 30th anniversary, ISPOR—The Professional Society for Health Economics and Outcomes Research will once again bring together patients, payers, providers, regulators, and industry leaders at its European conference, taking place this year in Glasgow on November 9–12, 2025. The theme of ISPOR Europe 2025, 'Powering Value and Access Through Patient-Centered Collaboration,' sets the tone for four days of practical, patient-focused discussions aimed at supporting healthcare access decisions across Europe.
To help the community prepare for the meeting, we are sharing an early preview of the program – highlighting what to expect, the key themes set to take center stage, and the sessions likely to shape conversations in Glasgow. As a media partner for ISPOR Europe 2025, The Evidence Base will also publish more detailed previews in the weeks ahead. follow us on LinkedIn and register for free to become a member of The Evidence Base community and receive the latest news as it is published.
Program highlights
ISPOR Europe 2025 is one of the largest international meetings focused on health economics and outcomes research (HEOR), health technology assessment (HTA), real-world evidence (RWE), market access, and related areas. The program, featuring a broad range of learning formats including plenaries, spotlight sessions, issue panels, workshops, and breakout discussions, is being developed under the guidance of three co-chairs, whose backgrounds span patient advocacy, clinical research, and healthcare investment, providing a broad range of perspectives:
- Maria Dutarte (European Patients’ Academy on Therapeutic Innovation – EUPATI)
- Denise Lacombe (European Organisation for Research and Treatment of Cancer – EORTC)
- Joep Muijrers (Gilde Healthcare Partners)
Sessions on patient-centered research
With growing recognition that patients’ perspectives, preferences, and lived experiences are essential to shaping meaningful healthcare decisions, these sessions explore how evidence can be generated and applied in ways that reflect what matters most to patients. From the use of patient experience data in regulatory and access decisions to advances in preference elicitation, digital health, and pragmatic trials, the program highlights how embedding the patient voice can strengthen both the relevance and impact of evidence across Europe.
- Patient Engagement in Healthcare Investments—A Promise or a Practice? (Monday, November 10)
Speakers: Joep Muijrers (Gilde Healthcare Partners), Carole Longson, Steffen Thirstrup (European Medicines Agency), David H-U Haerry (Positivrat), Luc Truyen (Argenx) - Partnering for Progress: Advancing Patient-Centered Evidence in HEOR (Monday, November 10)
Speakers: Alan Balch (Patient Advocate Foundation / National Patient Advocate Foundation), Maria Dutarte (EUPATI), Angie Botto-van Bemden (Musculoskeletal Research International) - Patient Experience Data for Evidence Generation to Support Regulatory and Access Decision Making (Monday, November 10)
Speakers: Steffen Thirstrup (European Medicines Agency), Denise Umuhire (European Medicines Agency), Carla Torre (University of Lisbon) - Patient-Centric Approaches when Using Digital Health Technology in Drug Development (Tuesday, November 11)
Speakers: Sarah Ernst (Sanofi), Marie McCarthy (Novartis), Christine Guo (Ametris) - Delay in Patients’ Access is the Price of Misalignment: Why Evidence Must Speak Also the Language of Payers and Patients (Wednesday, November 12)
Speakers: Cristina Masseria (Aesara), Adrian Cassidy (Novartis), Entela Xoxi (Independent Consultant), Maria Dutarte (EUPATI) - Embedding the Patient Voice within EU HTA: How Can We Balance Inclusivity, Representativeness and Scientific Rigour? (Wednesday, November 12)
Speakers: Ruairi O'Donnell (Cencora), Matteo Scarabelli (EFPIA), Antonella M Cardone (Cancer Patients Europe), Justin Doan (Pfizer)
Sessions on real-world evidence
Regulators and HTA bodies are now looking more closely at when and how RWE can be considered decision-grade, while advances in data linkages, causal methods, and AI-driven tools are expanding what is possible. Sessions at ISPOR Europe 2025 will focus on how the role of RWE is evolving, examining methodological innovations, regulatory expectations, and the practical applications needed to ensure that evidence generated from real-world settings can meaningfully inform access and improve patient outcomes.
- The Evidence Was There. So Why Didn’t It Matter? (Monday, November 10)
Speakers: Luis Prieto (Novartis), Mona Khalid, Clark Paramore (Biogen), Miguel Hernán (Harvard T.H. Chan School of Public Health) - Real-World Evidence – From the Clinician’s Perspective (Monday, November 10)
Speakers: Susan A. Oliveria (Thermo Fisher Scientific), Eleftherios Samartzis (University Hospital Zürich), John S Sampalis (PPD) - Swimming in the Sea of RWE Guidance: Debating a Path Forward (Tuesday, November 11)
Speakers: C Daniel Mullins (University of Maryland School of Medicine), Laura Pizzi (ISPOR), Sandipan Bhattacharjee (Bayer US), Ashley Jaksa (ex-Aetion) - Harmonizing and Enabling Cross-Border Real-World Evidence Studies in Europe (Tuesday, November 11)
Speakers: Ashwin Kumar Rai (Thermo Fisher Scientific), Miren Taberna Saiz, Sandrine Bourguignon (RWEality), Michael Hurst (Bristol Myers Squibb) - RWE in European Healthcare Decision Making—What’s in it for Patients? (Wednesday, November 12)
Speakers: Karen Facey (University of Edinburgh), Maria Dutarte (EUPATI), Pall Jonsson (NICE), Sofie Gustafsson (Pfizer), Renske Los (Erasmus MC)
Sessions on joint clinical assessment
As the EU begins implementing the new HTA Regulation, attention is turning to lessons from its early roll-out. Sessions on joint clinical assessment at ISPOR Europe 2025 will explore how Member States and stakeholders can collaborate to build consistent, transparent, and efficient evaluations that support timely patient access across Europe.
- Outcome Assessment in Rare Diseases: Is JCA Breaking the Silos or Perpetuating the Chaos? (Tuesday, November 11)
Speakers: Laura Sawyer (Symmetron), Milad Karimi (BioMarin), Steffen Thirstrup (European Medicines Agency), Olivier Chassany (Assistance Publique–Hôpitaux de Paris – AP-HP) - Accelerating Patient Access to Innovations in Europe: Is it Possible to Integrate the JCA into Diverse HTA Systems? (Tuesday, November 11)
Speakers: Ruairi O'Donnell (Cencora), Anja E Schiel (Norwegian Medicines Agency), James Ryan (AstraZeneca), Rod Taylor - Optimal Strategies for Predicting and Consolidating PICOs: One Best Method or a Blended Approach? (Tuesday, November 11)
Speakers: Pamela Vo (EVERSANA), Michal Stanák (National Institute for Value and Technologies in Health Care), Zsombor Zrubka (Óbuda University), Michael Happich (Eli Lilly) - A New Era for EU HTA: What Can the EU HTAR Learn from the EMA’s Path to Harmonization? (Tuesday, November 11)
Speakers: Wim Goettsch (Utrecht University; Zorginstituut Nederland), Neil McAuslane (Centre for Innovation in Regulatory Science), Anja E Schiel (Norwegian Medicines Agency), Ansgar Hebborn (Roche Products Ltd) - Mind the Gaps: Managing Missing PRO Data in the Era of JCA for HTA Submissions (Tuesday, November 11)
Speakers: Miranda Cooper (AstraZeneca), Neil Hawkins (University of Glasgow), Olivier Chassany (Assistance Publique–Hôpitaux de Paris – AP-HP), Gianluca Baio (University College London)
Sessions on AI in HEOR
As AI becomes increasingly relevant to evidence generation, sessions at ISPOR Europe 2025 will explore both the opportunities and the challenges, with a focus on practical applications, governance, and the implications for patient-centered research and decision-making.
- Transparent, Traceable and Reliable Generative AI in HEOR: A Hands-On Workshop on Retrieval-Augmented Generation (RAG) for Evidence Generation (Monday, November 10)
Speakers: Bill Malcolm (Bristol Myers Squibb), Rajdeep Kaur (Pharmacoevidence Pvt Ltd), Sven L Klijn (Bristol Myers Squibb), Pall Jonsson (NICE)
- AI in CEE Health System Decision Making: Can Payers, Patients, and Policy Align for Smarter Access? (Monday, November 10)
Speakers: Vladimir Guzvic (Health Insurance Fund of Republic of Srpska), Anna Kowalczuk (Agency for Health Technology Assessment and Tariff System), Maciej Grys (Certara), Kevin Kallmes (Nested Knowledge) - Building Multi-Agent AI Systems to Reduce Subject Matter Expert Burden in Health Economics Research (Tuesday, November 11)
Speakers: J Jaime Caro (Thermo Fisher Scientific), Brian Reddy (Pfizer), Baris Deniz (Alde Solutions) - Trusting a Machine? Opportunities and Challenges to Using Artificial Intelligence in Qualitative Patient Research (Tuesday, November 11)
Speakers: Christina Silver (University of Surrey), Karen Bailey (Evidera), Paul Cordero (Sanofi) - Navigating the Global Pricing Policy Landscape and Leveraging AI for Strategic Insights (Tuesday, November 11)
Speakers: David Ringger (Cencora), Neil Grubert (Neil Grubert Consulting), Casper Paardekooper (Vintura), Leanna Baker Williams (Cencora) - Battle of the Bots: Navigating the Landscape of AI-Enabled Systematic Literature Review Platforms (Wednesday, November 12)
Speakers: Ramiro E. Gilardino (Independent), Angeline Dhas, Ranita M Tarchand (Nested Knowledge)
Coverage by The Evidence Base
Our editorial team will be on site in Glasgow to cover some of these key sessions, share daily highlights and speak with presenters and partners. Follow The Evidence Base on LinkedIn for live updates throughout the meeting. For exclusive post-event analysis and session round-ups, register on our site to receive regular updates.
Partner with us
Our ISPOR coverage consistently attracts strong engagement across the HEOR and RWE community. We offer complimentary and sponsored opportunities to extend the reach of your work – from expert interviews and session deep-dives to webinars and downloadable summaries. If you are speaking at ISPOR Europe 2025 and would like to explore options, please reach out to Dionne Basterfield.